AstraZeneca submits Axanum marketing application
LONDON (MarketWatch) — Drugmaker AstraZeneca said Friday that it has submitted a marketing authorisation application in the European Union for a product combining low-dose acetylsalicylic acid and the active ingredient of its Nexium drug. The product will be used for the prevention of cardio and cerebrovascular events in patients requiring continuous low-dose ASA treatment who are at risk of …
Read more on Market Watch
Recent Comments